Analysis of the potential contribution of estrogen receptor (ER) ? in ER cytosolic assay of breast cancer

Brouillet, Jean‐Paul; Dujardin, M.; Chalbos, Dany; Rey, Jean-Marc; Grenier, Jean; Lamy, Pierre‐Jean; Maudelondé, Thierry; Pujol, Pascal

doi:10.1002/1097-0215(20010720)95:4<205::aid-ijc1035>3.0.co;2-y

Cited by 18 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, at a comparable amplification cycle number, ERb expression was weaker than the one of ERa (see the Materials and methods section). This confirms previous work from our laboratory, demonstrating that ERb expression was weak in breast tumors and that ER-positive samples are indeed ERa-positive (Brouillet et al, 2001). We observed that most of the ER-negative tumors (5/7) expressed detectable levels of IL-8, even though two of them did not contain significant levels of IL-8 (Figure 4a and c).…”

Section: Resultssupporting

confidence: 92%

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells

et al. 2003

View full text Add to dashboard Cite

Estrogen-receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors. Here, we demonstrate, that interleukin-8 (IL-8) was clearly overexpressed in most ER-negative breast, ovary cell lines and breast tumor samples tested, whereas no significant IL-8 level could be detected in ER-positive breast or ovarian cell lines. We have also cloned human IL-8 from ERnegative MDA-MB-231 cells, and we show that IL-8 produced by breast cancer cells is identical to monocytederived IL-8. Interestingly, the invasion potential of ERnegative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells by two fold, thus confirming the invasion-promoting role of IL-8. On the other hand, exogenous expression of estrogen receptors in ERnegative cells led to a decrease of IL-8 levels. In summary, our data show that IL-8 expression is negatively linked to ER status of breast and ovarian cancer cells. We also support the idea that IL-8 expression is associated with a higher invasiveness potential of cancer cells in vitro, which suggests that IL-8 could be a novel marker of tumor aggressiveness.

show abstract

Section: Resultssupporting

confidence: 92%

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells

et al. 2003

View full text Add to dashboard Cite

show abstract

“…To our knowledge, no studies assessing crossreactivity of this antibody with ER␤ have been performed to date (verbal confirmation received from Novocastra June 20, 2005). In contrast, the study by Rasbridge et al used the H222 clone marketed by Abbott Laboratories (North Chicago, IL), which demonstrated no cross-reactivity with ER␤, 18 whereas the studies by Devouassoux-Shisheboran et al and Sorensen et al used the 1D5 clone from Dako Corporation, which also has been shown to have no crossreactivity with ER␣ (Dakocytomation web site, available from URL: http://www.dakocytomation.us/ prod_downloadpackageinsert. pdf?objectidϭ104482002 [accessed June 20, 2005]).…”

Section: Discussionmentioning

confidence: 99%

Estrogen receptor‐β expression in extraabdominal fibromatoses

Deyrup

Tretiakova

Montag

2005

Cancer

123

View full text Add to dashboard Cite

BACKGROUNDEarly experiments using ligand‐binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis.METHODSTo verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERβ.RESULTSAll 40 cases of extraabdominal fibromatosis were at least focally positive for ERβ. Thirty‐three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11–50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERα.CONCLUSIONSAlthough extraabdominal fibromatosis does not express ERα, there appears to be nearly uniform expression of ERβ. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses. Cancer 2006. © 2005 American Cancer Society.

show abstract

“…All seven laboratories in Sweden analyzing ER and PR content used an enzyme immunoassay (Abbott Laboratories) on cytosol samples. The method used for assessing ER content was ERa specific (6). Three laboratories reported amount of receptor per microgram DNA, three laboratories reported amount of receptor per milligram protein, and one laboratory reported both.…”

Section: Methodsmentioning

confidence: 99%

Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women

Rosenberg

Einarsdóttir

Friman³

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

106

116

View full text Add to dashboard Cite

The effect of classic breast cancer risk factors on hormone receptor-defined breast cancer is not fully clarified. We explored these associations in a Swedish population-based study. PRÀ tumors (OR, 1.3; 95% CI, 0.7-2.5). In conclusion, other risk factors were similarly related to breast cancer regardless of receptor status, but high age at first birth, substantial weight gain in adult age, and use of menopausal estrogen-progestin therapy were more strongly related to receptor-positive breast cancer than receptornegative breast cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2482 -8)

show abstract

Analysis of the potential contribution of estrogen receptor (ER) ? in ER cytosolic assay of breast cancer

Cited by 18 publications

References 13 publications

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells

Estrogen receptor‐β expression in extraabdominal fibromatoses

Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women

Contact Info

Product

Resources

About